医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NTCELL® Continues to Reverse the Progression of Parkinson’s Disease – One Year after Implant

2016年01月27日 AM10:54
このエントリーをはてなブックマークに追加


 

SYDNEY & AUCKLAND, New Zealand

Over a year after treatment all four patients who took part in Living Cell Technologies Limited’s Phase I/IIa clinical study of NTCELL® for Parkinson’s disease remain well, and at 58 weeks post-implant there are no safety concerns.

In all four patients NTCELL treatment has stopped the progression of Parkinson’s disease as measured by globally accepted and validated neurological rating scales.

After 58 weeks there is a clinically and statistically significant improvement in all the patients’ neurological score from their pre-implant baseline. A graph of this is viewable on the ASX website here.

Parkinson’s disease progression is measured by a neurological rating scale, Unified Parkinson’s Disease Rating Scale (UPDRS). The UPDRS score increases by approximately 4 to 5 points each year as Parkinson’s disease progresses.

NTCELL’s ability to decrease UPDRS by an average of 16 points after 58 weeks is clinically significant, representing a 3 to 4 year reversal of neurological deterioration. In the first patient the improvement is maintained at 74 weeks after NTCELL implant.

Dr Ken Taylor, chief executive, says the sustained improvement of the patients is pleasing, particularly as no other treatment has been able to maintain long term reversal of the effects of Parkinson’s disease.

“We are delighted with the continued positive outcome of the study. It certainly adds anticipation and motivation to our authorised Phase IIb study, which we plan to initiate on 24 February.”

The planned Phase IIb study aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group.

“Our goal is to obtain provisional consent and launch NTCELL as the first disease modifying treatment for Parkinson’s disease in 2017,” says Dr Taylor.

For further information: www.lctglobal.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160126006784/en/

CONTACT

Media Contact:
Botica Butler Raudon Partners
Rachael
Joel
Tel: +64 9 303 3862
Mobile: +64 21 403 504
rachaelj@botica.co.nz

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • DSG, Inc. Accelerates Growth with Opening of New Office in Bangalore, India
  • 仁和集团与APR应用制药研究公司公布协议在中国市场销售治疗偏头痛创新药
  • 武田连续第二年入选全球可持续发展最佳企业百强榜单
  • InFo 124M – 瑞士生产的用于白内障手术的延伸焦深人工晶体
  • 2017 Taiwan WHO Simulation Kicks off at NCKU with 240 Medical Students Sharing